The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikeda, Y.
Right arrow Articles by Ohigashi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikeda, Y.
Right arrow Articles by Ohigashi, H.
The Journal of Immunology, 2007, 178: 4854-4864.
Copyright © 2007 by The American Association of Immunologists, Inc.

Aggregated Ursolic Acid, a Natural Triterpenoid, Induces IL-1beta Release from Murine Peritoneal Macrophages: Role of CD361

Yasutaka Ikeda*, Akira Murakami*, Yoshinori Fujimura{dagger}, Hirofumi Tachibana{dagger}, Koji Yamada{dagger}, Daisaku Masuda{ddagger}, Ken-ichi Hirano{ddagger}, Shizuya Yamashita{ddagger} and Hajime Ohigashi2,*

* Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto, Japan; {dagger} Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Fukuoka, Japan; and {ddagger} Department of Cardiovascular Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
IL-1beta has been shown to play a pivotal role in the development of inflammatory disorders. We recently found that a natural triterpene, ursolic acid (UA), enhanced MIF release from nonstimulated macrophages. In this study, we examined the effects of UA on the production of several cytokines in resident murine peritoneal macrophages (pM{phi}). UA increased the protein release of IL-1beta, IL-6, and MIF, but not of TNF-{alpha}, in dose- and time-dependent manners. This triterpene also strikingly induced the activation of p38 MAPK and ERK1/2 together with that of upstream kinases. The release of UA-induced IL-1beta was significantly inhibited by the inhibitors of p38 MAPK, MEK1/2, ATP-binding cassette transporter, and caspase-1. Furthermore, UA induced intracellular ROS generation for IL-1beta production, which was suppressed by an antioxidant. Pretreatment with an anti-CD36 Ab significantly suppressed IL-1beta release, and surface plasmon resonance assay results showed that UA bound to CD36 on macrophages. In addition, the amount of IL-1beta released from UA-treated pM{phi} of CD36-deficient mice was markedly lower than that from those of wild-type mice. Interestingly, UA was found to aggregate in culture medium, and the aggregates were suggested to be responsible for IL-1beta production. In addition, i.p. administration of UA increased the levels of IL-1beta secretion and MPO activity in colonic mucosa of ICR mice. Taken together, our results indicate that aggregated UA is recognized, in part, by CD36 on macrophages for generating ROS, thereby activating p38 MAPK, ERK1/2, and caspase-1, as well as releasing IL-1beta protein via the ATP-binding cassette transporter.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Monocytes/macrophages are key mediators of wound repair, tissue remodeling, and inflammation and resident macrophages) are considered to be the front line of immunological defense against pathogens. These cells have prominent roles such as Ag presentation, phagocytic, microbicidal, tumoricidal, and secretory functions, as well as innate immunity, by initiating inflammatory and immune responses (1, 2). Macrophages produce a variety of inflammatory cytokines, including IL-1beta, IL-6, TNF-{alpha}, and macrophage migration inhibitory factor (MIF)3 (3), which recruit polymorphonuclear leukocytes from the vasculature into the inflammatory site for effective eradication of offending pathogens (4). Although they are essential for the host defense system, excessive production at an inflammatory site may lead to chronic diseases such as inflammatory bowel disease, which includes ulcerative colitis, Crohn’s disease, and neoplasm (5, 6).

IL-1beta, an antiapoptotic and proinflammatory cytokine, is one of the most pronounced mediators of inflammatory reactions and is primarily produced in activated monocytes or macrophages (7). Pro-IL-1beta, a precursor of IL-1beta (8) that is detected in the cytosol of resident macrophages, is biologically inactive with a molecular mass of ~33 kDa. Upon stimulation, it is cleaved via an enzymatic procession into a 17-kDa mature functional form by the IL-1beta-converting enzyme (ICE, also known as caspase-1) (9, 10). Following ICE cleavage, active IL-1beta is released from macrophages through the ATP binding cassette transporter (ABC)A1-dependent and -independent pathways (11, 12). Enhanced IL-1beta production has been detected at both mRNA and protein levels in human inflammatory bowel disease (13), rheumatoid arthritis (14), and dextran sulfate sodium (DSS)-induced colitis murine model (15). In our previous study, IL-1beta levels were found to be profoundly increased in both colonic mucosa and peritoneal macrophages (pM{phi}) in mice with DSS-induced colitis (16). Thus, pM{phi}-derived IL-1beta may be closely and critically associated with disease pathology.

Triterpenoids are ubiquitously distributed throughout the plant kingdom, and some are increasingly being used for medicinal purposes for a variety of clinical diseases in many Asian countries as antitumor, anti-inflammatory, and immunomodulatory agents (17, 18, 19). However, the molecular mechanisms underlying those activities remain to be fully elucidated. Ursolic acid (UA; 3beta-hydroxy-12-urs-12-en-28-oic acid) is a pentacyclic triterpene carboxylic acid found in various plants, including Rosmarinus officinalis and Glechoma hederaceae (19, 20), in the form of an aglycones or as glycosides (19, 20, 21, 22, 23). It is well known to possess many important biological functions, such as anticancer, anti-inflammatory, hepatoprotective, antiulcer, hypolipidemic, and anti-atherosclerotic activities, as well as others (17, 20, 24, 25). Furthermore, it has been reported that UA attenuated the expression of inducible NO synthase (iNOS) and cyclooxygenase-2 expression via NF-{kappa}B repression in LPS- or IFN-{gamma}-activated mouse macrophages (26). In contrast, You et al. (27) recently reported that UA induced NO and TNF-{alpha} production via NF-{kappa}B activation in resting RAW264.7 mouse macrophages. Along a similar line, we recently reported that UA promoted the release of MIF via ERK2 activation in the same cell line (28). Those findings imply that the effects of UA on NF-{kappa}B activities are dependent on the biological status of the target macrophages. This background led us to the present investigation of the potential proinflammatory effects of UA in pM{phi}. Our results indicate for the first time that aggregated UA is recognized by CD36 for generating ROS, thereby activating p38 MAPK, ERK1/2, and caspase-1 and releasing IL-1beta protein in pM{phi}.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Cells and mice

RAW 264.7 macrophages were obtained from American Type Culture Collection. Male CD36-deficient (C57BL/6J) mice were provided by Dr. M. W. Freeman (Harvard Medical School, Boston, MA). Specific pathogen-free 5-wk-old female ICR mice and 9-wk-old male C57BL/6J mice were purchased from Japan SLC. On arrival, the mice were randomized and transferred to plastic cages containing sawdust bedding (five mice per cage), which was changed every third day. They were given MF rodent chow (Oriental Yeast) and fresh tap water ad libitum, which was freshly changed twice a week, and handled according to the Guidelines of the Regulation of Animals, as provided by the Experimentation Committee of Kyoto University. The mice were maintained in a controlled environment of 24 ± 2°C with a relative humidity of 60 ± 5% and a 12-h light/dark cycle (lights on from 06:00 to 18:00). All mice were quarantined for 1 wk before starting the experiments.

Reagents

DMEM, Opti-MEM, FBS, and TRIzol were purchased from Invitrogen Life Technologies. UA was obtained from Funakoshi. PD98059, SB203580, SP600125, SB202474 (negative control) inhibitors, diphenyleneiodonium (DPI) chloride, and YVAD-CHO came from Calbiochem. Glibenclamide, human leukocyte myeloperoxidase (MPO), o-dianisidine dihydrochloride, and hexadecyltrimethylammonium were obtained from Sigma-Aldrich. Abs were purchased from the following sources: rat anti-CXCL16 Ab was from TECHNE; goat anti-scavenger receptor (SR) class-A (SR-A), rabbit anti-CD36, rabbit anti-CD68, goat anti-IL-1beta, and goat anti-beta-actin Abs from Santa Cruz Biotechnology; rabbit anti-phospho-ERK1/2, rabbit anti-ERK1/2, rabbit anti-phospho-p38, rabbit anti-p38, rabbit anti-active JNK1/2, rabbit anti-JNK1/2, rabbit anti-phospho-MAPK/ERK kinase (MEK)1/2, rabbit anti-MEK1/2, rabbit anti-phospho-MAPK kinase (MKK) 3/6, rabbit anti-MKK3, rabbit anti-phospho-Raf-1, rabbit anti-Raf-1, and anti-rabbit Ab HRP-linked IgG Abs from Cell Signaling Technology; and anti-goat IgG from DakoCytomation. Oligonucleotide primers were synthesized by Proligo. Mouse IL-1beta ELISA and caspase-1 colorimetric assay kits were purchased from R&D Systems. Mouse IL-6 and mouse TNF-{alpha} ELISA kits were purchased from Endgen. A rat/mouse MIF immunoassay kit came from Sapporo ImmunoDiagnostic Laboratory. All other chemicals were purchased from Wako Pure Chemicals unless specified otherwise.

Cell culture

RAW 264.7 macrophages were grown in DMEM supplemented with 10% FBS, L-glutamine (330 µg/ml), penicillin (100 U/ml), and streptomycin (100 µg/ml) at 37°C under a humidified atmosphere of 95% air and 5% CO2. pM{phi} monolayers were prepared as described previously (29), with some modifications. Briefly, nontreated 6-wk-old female ICR mice were killed by cervical dislocation, and 10 ml of ice-cold DMEM containing 10% FBS, L-glutamine (330 µg/ml), penicillin (100 U/ml), and streptomycin (100 µg/ml) was injected i.p. Medium containing peritoneal exudates cells (PEC) was recollected and kept on ice. The suspended cells thus obtained were centrifuged at 800 x g for 5 min and resuspended with DMEM. Peritoneal exudate cells (5 x 106 cells/ml/well) were then seeded onto culture plates and allowed to adhere for 24 h at 37°C under a humidified atmosphere of 95% air and 5% CO2. After washing with PBS twice, nonadherent cells were removed, and the remaining monolayers were designated as pM{phi}. Cell viability was ≥90% in all experiments, unless specified otherwise.

Tissue harvest

At the end of each experiment, mice were killed by cervical dislocation, and the large intestines without the cecum were removed. After washing in ice-cold PBS, the specimens were placed on filter papers and opened with surgical scissors to remove their contents. The colonic mucosa was scraped off using a razor while the specimen was on ice, then frozen in liquid nitrogen until use, according to a method previously reported by Perdue et al. (30), with some modifications.

Protein determination

Total protein concentrations in the pM{phi} and tissue supernatants were determined using a DC protein assay (Bio-Rad) according to the protocol of the manufacturer (dilution factor = 50), with gammaglobulin used as the standard.

ELISA

pM{phi} were seeded onto a 96-well plate at a density of 1 x 106 cells/200 µl in 200 µl of DMEM, which included 10% FBS, L-glutamine (330 µg/ml), penicillin (100 U/ml), and streptomycin (100 µg/ml). The cells were cultured at 37°C under a humidified atmosphere of 95% air and 5% CO2. After 24 h, the cells were washed twice with PBS, and a serum-free medium was added. The cells were then treated with UA (4 or 20 µM), which was dissolved in DMSO (0.1% v/v, as a final concentration). Control cells were treated only with 0.1% (v/v) DMSO and showed no significant effect on the assay systems (data not shown). After incubation for 0, 1, 3, 6, 12, and 24 h, the supernatants, 5 µl for MIF and 50 µl for TNF-{alpha}, IL-1beta, and IL-6, were used for ELISA and examined according to the protocol of the appropriate kit. Alternatively, pM{phi} were pretreated with each specific inhibitor (see Fig. 4B) or Ab (see Fig. 5B) 30 min before UA treatment.


Figure 4
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 4. UA may activate NOX for generating intracellular ROS generation which, in turn, phosphorylates MAPKs in pM{phi}. A, UA induces DCFH-detectable peroxide generation in pM{phi}. pM{phi} from peritoneal exudates from nontreated female ICR mice were seeded onto one-chamber slides at a density of 1 x 106 cells/chamber, then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} were treated with DMSO (0.1%, v/v) or UA (4 or 20 µM) for 5 min. ROS generation was determined using a fluorescent probe, DCFH-DA, as described in Materials and Methods. The negative control cells were treated only with DMSO. *, p < 0.01 vs DMSO by Student’s t test. The experiments were repeated three times independently. B and C, Effects of an antioxidant, NOX inhibitor, and Ca2+ chelator on UA-induced IL-1beta production (B), and activation of Raf, MEK1/2, ERK1/2, MKK3/6, and p38 MAPK (C). pM{phi} from peritoneal exudates from nontreated female ICR mice were seeded onto 96- and 12-well plates at a density of 1 x 106 cells/dish (B) or 5 x 106 cells/dish (C), then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} were pretreated with DMSO (0.1%, v/v), 1 mM NAC, 10 µM DPI, or 5 mM EDTA for 30 min, followed by exposure to UA (4 µM) for 6 h (B) or 5 min (C). IL-1beta production (B) and MAPK activation (C) were examined by ELISA and Western blotting, respectively, as described in Materials and Methods. *, p < 0.01 vs DMSO; **, p < 0.05; ***, p < 0.01 vs UA by Student’s t test. Data are shown as the mean ± SD of three independent experiments, with one representative result shown (C).

 

Figure 5
View larger version (33K):
[in this window]
[in a new window]

  		FIGURE 5. Possible involvement of CD36 in UA-induced IL-1beta production. A, SR mRNA and protein expression in UA-stimulated pM{phi}. pM{phi} from peritoneal exudates from nontreated female ICR mice were seeded onto a 12-well plate at a density of 5 x 106 cells/dish, then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} were treated with UA (4 µM) for 0 or 6 h. SR mRNA and proteins were examined by RT-PCR and Western blotting, respectively, as described in Materials and Methods. The arrow indicates the band for CXCL16 protein. The experiments were repeated three times independently, with one representative result shown for each. Cyclophilin and beta-actin served as the internal standards. B, Effects of anti-SR Abs on IL-1beta production in pM{phi}. pM{phi} from peritoneal exudates from nontreated female ICR mice were seeded onto a 96-well plate at a density of 1 x 106 cells/dish, then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} were pretreated with the vehicle (nonspecific IgG), anti-CXCL16, anti-SR-A, anti-CD36, or anti-CD68 Abs (2.5 µg/ml each), followed by exposure to UA (4 µM) for 6 h. IL-1beta production was examined by ELISA, as described in Materials and Methods. *, p < 0.0005 vs DMSO; **, p < 0.005 vs UA by Student’s t test. Each value is shown as the mean ± SD of three replicated experiments. C, pM{phi} from CD36-deficient mice had lower levels of IL-1beta, IL-6, and MIF production as compared with those from wild-type mice. pM{phi} from peritoneal exudates from nontreated male C57BL/6J (wild-type) and CD36-deficient mice were seeded onto a 96-well plate at a density of 1 x 106 cells/dish, then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} were treated with DMSO (0.1%, v/v), UA (4 or 20 µM), or LPS (100 ng/ml) for 12 h. IL-1beta, IL-6, and MIF production was examined by ELISA, as described in Materials and Methods. {square}, wild type; {blacksquare}, CD36-deficient mice. *, p < 0.05 vs wild-type mice by Student’s t test. Each value is shown as the mean ± SD of three replicated experiments. D, UA binds to cell surface CD36 on mouse macrophages. RAW264.7 cells and pM{phi} were pretreated with nonspecific IgG or anti-CD36 Ab, then fixed on the sensor chip. The cell surface interactions of UA with immobilized RAW264.7 cells and pM{phi} were measured using a SPR biosensor, as described in Materials and Methods. UA was injected at a concentration of 0 or 20 µM for the indicated intervals.

 
Western blotting

To determine the expression of phospho-ERK1/2 (Thr202/Tyr204), ERK, phospho-p38 MAPK (Thr180/Tyr182), p38 MAPK, phospho-JNK1/2 (Thr183/Tyr185), JNK1/2, phospho-MEK1/2 (Ser217/221), MEK1/2, phospho-Raf (Ser259), Raf, phospho-MKK3/6 (Ser189/207), MKK3/6, proIL-1beta, SR-A, CD36, CD68, and CXCL16 in pM{phi}, the total cell lysate was subjected to Western blotting. beta-Actin served as the internal control. Cells (5.0 x 106) were treated with lysis buffer (protease inhibitor mixture, phosphatase inhibitor mixture (TaKaRa Bio), 10 mM Tris (pH 7.4), 1% SDS, and 1 mM sodium vanadate (V)), and the lysates were boiled for 5 min. Denatured proteins (40 µg) were separated using SDS-PAGE on a 10% polyacrylamide gel and then transferred onto Immobilon-P membranes (Millipore). After blocking overnight at 4°C in Block Ace (Dainippon Pharmaceutical), the membranes were first incubated with each Ab at dilutions of 1/1000. The second incubation was performed with HRP-conjugated secondary anti-rabbit IgG or anti-goat IgG Ab (1/1000 dilution each). The blots were developed using an ECL Advance Western blotting detection reagent (Amersham Biosciences). The intensity of each band was analyzed using NIH Image.

RT-PCR

Steady-state mRNA levels of CXCL16, SR-A type I, CD36, CD 68, and IL-1beta were detected by RT-PCR. pM{phi} were cultured at a density of 5 x 106 cells/2 ml for 24 h. Total cellular RNA was extracted from the cells using TRIzol reagent, then precipitated with isopropanol, washed with 70% (v/v) ethanol, and treated with DNase I (Invitrogen Life Technologies) to remove genomic DNA. A cyclophilin transcript served as the internal control. The primer sequences, PCR product sizes, and PCR conditions are listed in Table I. cDNA was synthesized using 1 µg of total RNA and an RNA PCR kit (Takara). Amplified cDNA was electrophoresed on 2% agarose gels and stained with SYBR Gold (Molecular Probes). Image analysis was performed using NIH Image. No PCR saturation was confirmed by titration of each cDNA amount (data not shown).


View this table:
[in this window]
[in a new window]

  		Table I. List of primer sequences, product size, cycles, and PCR conditions

 
Determination of intracellular ROS generation

pM{phi} were cultured at a density of 1 x 106 cells/200 µl for 24 h on one-chamber slides (GLASS/PS, 9 x 9; IWAKI). After washing, the cells were suspended in 200 µl of PBS and treated with 10 µM of 2,7'-dichlorofluorescein diacetate (DCFH-DA; Molecular Probes) for 5 min. Thereafter, the medium was discarded and the pM{phi} were washed twice with PBS, followed by exposure to DMSO or UA (final 4 or 20 µM) for 5 min. Negative control cells were treated only with DMSO and without DCFH-DA. UA-induced intracellular ROS generation was detected using a fluorescence microscope (Olympus).

Binding analysis using surface plasmon resonance (SPR) biosensor

Analysis of the interaction between UA and CD36 on the cell surface of macrophages was performed using the SPR biosensor SPR670 (Moritex). Mouse macrophage RAW264.7 cells (5 x 105 cells/ml) and pM{phi} (1.5 x 106 cells/ml) were immobilized on sensor chips, which had been pretreated with nonspecific IgG and anti-CD36 Ab (2.5 µg/ml each) in serum-free DMEM for 30 min. Following pretreatment, the medium was discarded and the chips were equilibrated in SPR running buffer, and 0.1% DMSO (v/v) in PBS (pH 7.4, flow rate = 30 µl/min). UA was diluted at 0 or 20 µM in SPR running buffer in 60-µl injection volumes and run on the chip at a flow rate of 30 µl/min. Binding was measured at 25°C for 2 min, followed by dissociation. The value of the angle was deducted from the binding signal of 0 µM UA and used as the binding strength.

HPLC analysis

UA (4 µM) was dissolved in DMSO (0.05–1%, v/v) and added to 50 ml of serum-free DMEM in a 50-ml centrifuge tube. After centrifugation at 2,500 x g for 5 min, UA was extracted separately from the supernatant and pellet with chloroform, with a recovery rate of ≥85% in each experiment. Each extract was concentrated in vacuo and dissolved in 200 µl of chloroform. The amount of UA was quantified by HPLC analysis on a YMC-Pack ODS-AQ column (150 x 4.6 mm inside diameter; YMC), which was eluted with 10% methanol in water at a flow rate of 1.0 ml/min. A standard curve was made using 0–8 µg of UA, with the peak area based on absorption of 210 nm. The amounts of UA derivatives (4 µM, 0.1% DMSO v/v) were analyzed under the same experimental conditions. Data are expressed by the distribution rates, which were calculated from the amounts of each fraction.

Animal treatment

Corn oil alone (n = 8) or UA suspended in 200 µl of corn oil was administrated by i.p. injection to specific pathogen-free 5-wk-old female ICR mice daily at a dose of 50 (n = 6), 100 (n = 6), or 200 (n = 9) mg/kg body weight for 8 days. Twenty-four hours after the final administration, pM{phi} monolayers were separately prepared as described above and seeded onto a 96-well plate at a density of 1 x 106 cells/200 µl, followed by incubation for 24 h at 37°C under a humidified atmosphere of 95% air and 5% CO2. After the cells were washed twice with PBS, serum-free medium (200 µl) was added. The cells were then incubated for another 24 h, and the supernatant (50 µl) was used for measuring IL-1beta with ELISA, as described above. After preparation of pM{phi}, the mucosa layer removed from the colon was homogenized (10 mg/300 µl) in ice-cold PBS using a homogenizer (UP 50H; Hielscher). Homogenates were frozen in liquid nitrogen and thawed using a sonicator (EYELA). These procedures were repeated three times, then the homogenate was centrifuged at 20,000 x g for 30 min at 4°C to obtain a supernatant. Each supernatant (50 µl) was subjected to ELISA, and the amounts of IL-1beta were measured according to the protocol of the kit.

MPO assay

MPO activity was measured as an index of inflammatory cell infiltration in the colonic mucosa using a previously reported method (31), with some modifications. The mucosal layer (~10 mg) was homogenized in 500 µl of 50 mM potassium phosphate buffer containing 0.5% hexadecyltrimethylammonium bromide (pH 6.0) using a homogenizer. Homogenates were frozen in liquid nitrogen and thawed using a sonicator (EYELA). The freeze-thaw cycle was repeated three times, then each homogenate was centrifuged at 20,000 x g for 30 min at 4°C to obtain a supernatant, which was used to measure MPO activity. MPO in the sample was activated by 0.0005% H2O2 in potassium phosphate buffer solution containing 0.5 mM o-dianisidine dihydrochloride (pH 6.0). The change in absorbance at 460 nm was measured using a spectrophotometer (Smart Spec; Bio-Rad) and converted to MPO activity using the standard curve for human leukocyte MPO. MPO activity was normalized further to the total protein content of the supernatant, as measured with a DC protein assay. Activity is expressed as units of MPO activity per milligram of protein.

Statistical analysis

Each experiment was performed at least three times, and the data are shown as the mean ± SD where applicable. Statistically significant differences between groups in each assay were determined using Student’s t test (two-sided).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
UA causes release of IL-1beta, IL-6, and MIF protein from pM{phi}

To investigate the effects of UA on proinflammatory cytokine release into medium, pM{phi} were treated with UA (0, 4, and 20 µM) for 0–24 h and examined with ELISA. As shown in Fig. 1, the levels of IL-1beta, IL-6, and MIF protein in pM{phi} treated with UA (4 and 20 µM) were increased in concentration- and time-dependent manners in the medium (14- to ~44-fold for IL-1beta; 2.7- to ~9.8-fold for IL-6; 7.4- to ~28-fold for MIF from 6 to 24 h), as compared with the vehicle-treated cells. In contrast, TNF-{alpha} was not detectable (<50 pg/mg) under any of the experimental conditions (data not shown). Although viability of the cells treated with UA (20 µM) for 24 h was decreased by 60%, that of the others was maintained at ≥90% in each experiment (data not shown).


Figure 1
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 1. UA releases IL-1beta (A), IL-6 (B), and MIF (C) protein in pM{phi} in a concentration- and time-dependent manners. pM{phi} from peritoneal exudates from nontreated female ICR mice were seeded onto a 96-well plate at a density of 1 x 106 cells/dish, then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} obtained were treated with DMSO (0.1%, v/v) or UA (4 or 20 µM) for 0, 1, 3, 6, 12, or 24 h. Supernatants were collected and the amounts of IL-1beta, IL-6, and MIF protein were determined by ELISA, as described in Materials and Methods. ({diamond}) DMSO; ({blacktriangleup}) UA (4 µM); ({blacksquare}) UA (20 µM). *, p < 0.01, and **, p < 0.001 vs DMSO by Student’s t test. Data are shown as the mean ± SD of three independent experiments.

 
UA activates Raf/MEK/ERK and MKK3/p38 MAPK pathways

Subsequently, we explored the molecular mechanisms underlying IL-1beta production by UA. To determine whether UA activates MAPK pathways, which are known to regulate the induction and production of proinflammatory cytokines, pM{phi} were treated with UA (4 µM) for 0–30 min, and both the inactive and activated forms of Raf-1, MEK1/2, ERK1/2, MKK3/6, p38 MAPK, and JNK1/2 were analyzed by Western blotting using Abs specific for each target protein. UA strikingly induced both Raf-1 and MEK1/2 activation within 2 min and that of ERK1/2 within 5 min, as compared with the nontreated cells (Fig. 2). Similarly, both MKK3/6 and p38 MAPK were activated within 2 min, whereas phosphorylation of JNK1/2 was not observed. The expression levels of the inactive forms of each protein kinase remained constant.


Figure 2
View larger version (32K):
[in this window]
[in a new window]

  		FIGURE 2. UA triggers activation of both the ERK1/2 and p38 MAPK, but not JNK1/2, pathways in pM{phi}. pM{phi} from peritoneal exudates from nontreated female ICR mice were seeded onto a 12-well plate at a density of 5 x 106 cells/dish, then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} were treated with UA (4 µM) for 0, 2, 5, 10, or 30 min. The intensity of each band was analyzed by Western blotting, as described in Materials and Methods. The experiments were repeated three times independently, with representative results shown. beta-Actin served as the internal standard.

 
Involvement of ERK1/2, p38 MAPK, caspase-1, and ABC transporter in UA-induced IL-1beta production

The production of a number of proinflammatory cytokines is regulated by transcription, translation, and posttranslation mechanisms. Caspase-1 is the rate-limiting enzyme responsible for the conversion of pro-IL-1beta to its active form. The effects of UA on the levels of IL-1beta mRNA, proIL-1beta protein, and caspase-1 activation were examined using RT-PCR, Western blotting, and ELISA, respectively. As shown in Fig. 3, A and B, IL-1beta mRNA and proIL-1beta protein were detected in a constitutive manner at low levels in nontreated pM{phi}. Those treated with 4 µM UA for 3 and 6 h were markedly up-regulated, whereas, intriguingly, the levels diminished after 12 h. Furthermore, to determine whether the ERK1/2 and p38 pathways are associated with those up-regulations, a pharmacological approach was used using each kinase-specific inhibitor. Pretreatment with 20 µM PD98059 (a MEK1/2 inhibitor) and SB203580 (a p38 MAPK inhibitor) for 30 min abolished the UA-induced increase in expression of IL-1beta mRNA and pro-IL-1beta protein (Fig. 3, A and B). In addition, PD98059 (20 µM), SB203580 (20 µM), glibenclamide (ABC transporter inhibitor, 20 µM), and Ac-YVAD-CHO (caspase-1 inhibitor, 20 µM), but not SB202474 (MAPK negative control, 20 µM), markedly reduced the level of UA-induced IL-1beta secretion (Fig. 3C).


Figure 3
View larger version (23K):
[in this window]
[in a new window]

  		FIGURE 3. A–C, Possible involvement of ERK1/2, p38 MAPK, caspase-1, and ABC transporter in UA-induced IL-1beta production pathway. A and B, Effects of kinase inhibitors on UA-induced IL-1beta mRNA expression (A) and pro-IL-1beta protein (B). pM{phi} from peritoneal exudates from nontreated female ICR mice were seeded onto a 12-well plate at a density of 5 x 106 cells/dish, then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} were pretreated with DMSO (0.1%, v/v), 20 µM PD98059 (PD), or 20 µM SB203580 (SB) at 37°C for 30 min before exposure to UA (4 µM) for 0, 3, 6, and 12 h. The negative control cells were treated only with 0.1% DMSO. Following the specified times, the cells were lysed, and IL-1beta mRNA expression (A) and protein production (B) were analyzed by RT-PCR and Western blotting, respectively, as described in Materials and Methods. *, p < 0.01; **, p < 0.001 vs DMSO, ***, p < 0.001 vs UA by Student’s t test. Values are shown as the mean ± SD of three independent experiments, with representative results shown. C, Effects of specific and nonspecific inhibitors on UA-induced IL-1beta production. pM{phi} from peritoneal exudates from nontreated female ICR mice were seeded onto a 96-well plate at a density of 1 x 106 cells/dish, then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} were pretreated with DMSO (0.1%, v/v), 20 µM PD98059 (PD), 20 µM SB203580 (SB), 20 µM MAPK-negative control (NEG), 20 µM glibenclamide (GC), or 20 µM Ac-YVAD-CHO (YVAD). The negative control cells were treated only with 0.1% DMSO (DM). After incubating at 37°C for 30 min, the pM{phi} were treated with UA (4 µM) for 6 h. IL-1beta production was examined by ELISA, as described in Materials and Methods. *, p < 0.01 vs DMSO; **, p < 0.01; ***, p < 0.005 vs UA by Student’s t test. Data are shown as the mean ± SD of three independent experiments.

 
UA-generated ROS mediate IL-1beta production

Oxidative stress has been demonstrated to induce the activation of MAPKs in many cell types; therefore, we investigated ROS generation in pM{phi} treated with UA (4 and 20 µM) for 5 min using DCFH-DA, a fluorescent probe. The rate of ROS-positive cells was increased in a concentration-dependent manner (31 and 43% at 4 and 20 µM, respectively) as compared with the vehicle-treated cells (Fig. 4A). Subsequently, we pretreated pM{phi} with the vehicle, N-acetyl-L-cysteine (NAC (an antioxidant), 1 mM), DPI (NADPH oxidase (NOX) inhibitor, 10 µM), or EDTA (Ca2+ chelator, 5 mM) for 30 min, followed by exposure to UA (4 µM) for 6 h. NAC, DPI, and EDTA markedly reduced UA-induced IL-1beta secretions by 52, 69, and 80%, respectively, together with a dramatic suppression of ERK1/2 and p38 MAPK pathways (Fig. 4, B and C).

Involvement of CD36 in UA-induced IL-1beta production

SRs, which mediate the endocytic uptake of modified forms of low-density lipoprotein, apoptotic cells, glycated proteins, and bacteria, are expressed on monocytes/macrophages, platelets, and certain microvascular endothelium (32, 33). Recently, we found that DSS induces IL-1beta production though a SR-mediated mechanism (K. H. Kwon, A. Murakami, and H. Ohigashi, submitted for publication). In this study, we examined the status of the mRNA and protein expressions of CXCL16, SR-A, CD36, and CD68 in pM{phi} with or without UA treatment. As shown in Fig. 5A, the expression of each was detected in a constitutive manner, and the levels were not changed by treatment with UA for 6 h. Next, we examined the effects of neutralizing Abs for SRs on UA-induced IL-1beta production. When pM{phi} were pretreated with an anti-CD36 Ab (2.5 µg/ml) for 30 min, IL-1beta production was significantly reduced by 56% as compared with the PBS-treated control, whereas nonspecific IgG and other SR Abs were inactive (Fig. 5B). In addition, when pM{phi} from CD36-deficient mice were treated with UA (4 or 20 µM) for 12 h, and the levels of IL-1beta, IL-6, and MIF released were markedly lower than from those of wild-type mice (Fig. 5C). In contrast, CD36 deficiency did not have an effect on LPS-induced cytokine production. Furthermore, SPR analysis showed that UA was bound to the cell surface of RAW264.7 cells and pM{phi} (Fig. 5D, nonspecific IgG), which was suppressed by treatment with the Ab for CD36, suggesting that UA interacts with CD36 located on the cell surface of macrophages.

Aggregated UA may induce IL-1beta production

The above results led us to hypothesize that UA aggregates in culture medium and is then recognized by CD36, leading to the release of IL-1beta protein, because SRs largely recognize macromolecules. To test our hypothesis, we prepared serum-free DMEM in which the amounts of aggregated UA were changed by increasing the concentration of DMSO (0.05–1%). After centrifugation, UA (4 µM) distribution throughout the supernatant and pellet was quantified by HPLC analysis (Fig. 6, upper panel). The amounts of aggregated UA were significantly decreased (47.0->17.8%) as DMSO concentration increased (0.05->1.0%). Interestingly, there was a marked decrease in UA-induced IL-1beta production when the pM{phi} were exposed to lower levels of aggregated UA (0.5 and 1.0% DMSO; Fig. 6, lower panel), suggesting that aggregated UA is in an active form for IL-1beta production.


Figure 6
View larger version (33K):
[in this window]
[in a new window]

  		FIGURE 6. Aggregated UA may be responsible for IL-1beta production. Upper graph, Amounts of aggregated UA in culture medium. UA (final concentration 4 µM) dissolved in DMSO (0.05–1%, v/v) was added to 50 ml of serum-free DMEM in a 50-ml centrifuge tube. After centrifugation at 2500 x g for 5 min, UA was extracted with chloroform from the supernatant and pellet. Each extract was concentrated in vacuo and dissolved in 200 µl of chloroform. The amount of UA was quantified by HPLC analysis using a YMC-Pack ODS-AQ column, which was eluted with 10% methanol in water at a flow rate of 1.0 ml/min and absorption was monitored at 210 nm. A standard curve using 0–8 µg of UA was prepared from the peak areas. The data are expressed as distribution rates, which were determined from the amount of UA in each fraction. {square}, dissolved UA; {square}, aggregated UA; Figure 6, dissolved plus aggregated UA. a, p < 0.01 vs corresponding rate of UA (0.05%, v/v) by Student’s t test. Each value is shown as the mean ± SD of three replicated experiments. Lower graph, pM{phi} from peritoneal exudates from nontreated female ICR mice were seeded onto a 96-well plate at a density of 1 x 106 cells/dish, then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} were treated with UA (final concentration 4 µM) dissolved in DMSO (0.05–1%, v/v) for 6 h. The supernatant was collected, and the amount of IL-1beta protein was determined by ELISA, as described in Materials and Methods. {square}, DMSO; {blacksquare}, UA. a, p < 0.01 vs corresponding DMSO; b, p < 0.01 vs UA (0.05%, v/v) by Student’s t test. Data are shown as the mean ± SD of three independent experiments.

 
Effects of UA derivatives on UA-induced IL-1betarelease

It is important to understand whether IL-1beta inducibility is specific for UA in light of the structural diversity of natural triterpenoids. To investigate this issue, we selected six natural and synthetic triterpenoids (Fig. 7A) and investigated their properties for aggregation and IL-1beta production in medium using HPLC analysis and ELISA, respectively. As shown in the upper panel of Fig. 7B, five UA derivatives and glycyrrhetinic acid exhibited distribution patterns in the supernatant and pellets similar to UA. However, surprisingly, they showed no notable potential for IL-1beta production (Fig. 7B, lower panel).


Figure 7
View larger version (31K):
[in this window]
[in a new window]

  		FIGURE 7. UA, but not its derivatives, induce IL-1beta release. A, Chemical structures of UA and UA derivatives. B, upper panel, Amounts of aggregated UA and its derivatives in culture medium. UA and its derivatives (final concentration 4 µM) were dissolved in DMSO (0.1%, v/v) and added to 50 ml of serum-free DMEM in a 50-ml centrifuge tube. After centrifugation at 2500 x g for 5 min, UA and its derivatives were extracted with chloroform from the supernatant and pellet. Each extract was concentrated in vacuo and dissolved in 200 µl of chloroform. The amounts of UA and its derivatives were quantified by HPLC analysis using a YMC-Pack ODS-AQ column, which was eluted with 10% methanol in water at a flow rate of 1.0 ml/min, and absorption was monitored at 210 nm. Standard curves using 0–8 µg of UA, and its derivatives were prepared from the peak areas. The data are expressed as the distribution rates, which were determined by the amount of UA or derivative in each fraction. {square}, dissolved triterpenes; {blacksquare}, aggregated triterpenes; Figure 7, dissolved plus aggregated triterpenes. Each value is shown as the mean ± SD of three replicated experiments. Lower panel, pM{phi} from peritoneal exudates from nontreated female ICR mice were seeded onto a 96-well plate at a density of 1 x 106 cells/dish, then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, the pM{phi} were treated with UA, and its derivatives (final concentration 4 µM) dissolved in DMSO (0.1%, v/v) for 6 h. The supernatant was collected, and the amount of IL-1beta protein was determined by ELISA, as described in Materials and Methods. a, p < 0.05; b, p < 0.005 vs 0 µM of UA (DMSO, 0.1%, v/v); c, p < 0.05 vs 4 µM UA; d, p < 0.001 vs 20 µM UA, by Student’s t test. Data are shown as the mean ± SD of three independent experiments.

 
IL-1beta production and MPO activity in UA-administrated mice

Finally, we investigated whether UA is able to stimulate pM{phi} (Fig. 8A) and colonic mucosa (Fig. 8, B and C) when injected i.p. into female ICR mice. As shown in Fig. 8A, a 24-h incubation of pM{phi} from mice administrated UA (50, 100, or 200 mg/kg) once a day for 8 days led to a marked dose-dependent increase in IL-1beta production (1.6-, 2.3-, and 3.3-fold, respectively) as compared with that of pM{phi} from vehicle-treated mice. In parallel, the levels of IL-1beta protein and MPO activity in colonic mucosa from mice administrated UA at 200 mg/kg were significantly increased by 3.0- and 2.0-fold, respectively, as compared with that of mucosa from vehicle-treated mice (Fig. 8, B and C).


Figure 8
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 8. Production of IL-1beta protein and MPO activity in pM{phi} (A) and colonic mucosa (B and C) from non-, vehicle-, and UA-treated ICR mice. A, UA administration (i.p.) to ICR mice induced IL-1beta production in pM{phi}. Corn oil alone or UA suspended in 200 µl of corn oil was administrated by i.p. injection to specific pathogen-free 5-wk-old female ICR mice daily at a dose of 50, 100, or 200 mg/kg body weight for 8 days. Twenty-four hours after the final administration, pM{phi} from non-, vehicle-, and UA-treated female ICR mice were seeded onto a 96-well plate at a density of 1 x 106 cells/dish, followed by incubation at 37°C for 24 h under a humidified atmosphere of 5% CO2. After washing, serum-free medium (200 µl) was added, and the cells were incubated for another 24 h, after which IL-1beta production was examined by ELISA, as described in Materials and Methods. *, p < 0.05; **, p < 0.01 vs corn oil alone by Student’s t test. Each value is shown as the mean ± SD of six to nine mice. B, IL-1beta production was increased in the mucosal layer of UA administration (i.p.) to ICR mice. Colonic mucosa samples were harvested from non-, vehicle-, and UA-treated ICR mice, as described in Materials and Methods, then homogenized (10 mg/300 µl) in ice-cold PBS to obtain supernatants. The amounts of IL-1beta protein were determined by ELISA, as described in Materials and Methods. *, p < 0.01 vs corn oil alone by Student’s t test. Each value is shown as the mean ± SD of results from six to seven mice. C, MPO activity was increased in the mucosal layer by UA administration (i.p.) to ICR mice. Colonic mucosa samples were harvested from non-, vehicle-, and UA-treated ICR mice, as described in Materials and Methods, then homogenized (10 mg/500 µl) in 50 mM potassium phosphate buffer containing 0.5% hexadecyltrimethylammonium bromide to obtain a supernatant. The MPO activities were measured, as described in Materials and Methods. *, p < 0.01 vs corn oil alone by Student’s t test. Each value is shown as the mean ± SD of results from six to seven mice.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In the present experiments, we found that UA markedly amplified ABC transporter-mediated IL-1beta secretion from murine pM{phi} at transcriptional, translational, and posttranslational levels, presumably through binding to CD36, ROS generation, the resultant activation of both the p38 MAPK and ERK1/2 pathways, and caspase-1 activation (Fig. 9). The action mechanisms underlying UA-induced IL-6 and MIF protein release may be similar to that for IL-1beta release (Fig. 1) because IL-6 was previously shown to be strongly induced by ROS generation and the p38 MAPK, ERK1/2, and NF-{kappa}B-signaling pathways (34, 35), and MIF production was induced by ROS-activated ERK1/2 (36).


Figure 9
View larger version (39K):
[in this window]
[in a new window]

  		FIGURE 9. Proposed molecular mechanisms by which UA induces IL-1beta production in murine pM{phi}. UA, but not aggregated OA or others, is recognized by CD36, and then ROS are intracellularly generated, presumably by NOX. This process triggers the activation of the Raf-1/MEK1/2/ERK1/2 and MKK3/6/p38 MAPK pathways for promoting transcription of the IL-1beta gene, leading to IL-1beta mRNA expression for intracellular pro-IL-1beta production. Intracellular pro-IL-1beta protein is then cleaved by ICE, and active IL-1beta is released via an ABC1 transporter-dependent pathway and exhibits its biological functions. The anti-CD36 Ab, NOX inhibitor DPI, antioxidant NAC, MEK1/2 inhibitor PD98059, p38 MAPK inhibitor SB203580, caspase-1 inhibitor YVAD-CHO, and ABC transporter inhibitor glibenclamide each have potential to block or attenuate these UA-induced molecular events.

 
SRs, including SR-A, CD36, and CD68, have been reported to recognize negative-charged, high-m.w. substances, such as oxidized low-density lipoprotein (oxLDL), DSS, and amyloid beta (33, 37, 38). Nishimura et al. (39) showed that oxLDL binding to SRs may generate intracellular ROS production through NOX activation, thereby activating NF-{kappa}B. CD36, originally identified as glycoprotein IV on platelets, is an integral membrane protein that has multiple ligands, including oxLDL, apoptotic cells, and long-chain fatty acids (40), and is expressed on monocytes/macrophages (41), platelets (42), and certain types of microvascular endothelia (43). In this study, the levels of CD36 mRNA and protein, both of which were expressed in a constitutive manner, did not change following UA treatment (Fig. 5A), while a previous study found that ligand-binding induced oxidative stress up-regulated SR gene expression, thereby promoting the uptake of oxLDL (44).

SPR biosensors have been increasingly used for real-time analysis of the binding between solubilized molecules and molecules immobilized on the surface of a biosensor chip without any labeling based on changes in the refractive index of the biospecific surface (45). Our analysis with the biosensor indicated that UA bound to pM{phi} and that binding was inhibited by treatment with the anti-CD36 Ab (Fig. 5D). Furthermore, the production of IL-1beta was suppressed by treatment with that Ab (Fig. 5B) and decreased in pM{phi} of CD36-deficient mice, as compared with wild-type mice (Fig. 5C). To the best of our knowledge, this is the first report showing that CD36 is one of the membrane receptors for a triterpenoid, while it was previously reported that UA binds to the hydrophobic region of the dimeric interface of TGF-beta1 (46). However, it remains to be determined whether UA also binds with other SRs or proteins because the anti-CD36 Ab and CD36 deficiency did not abolish IL-1beta protein release and UA binding (Fig. 5, B–D). Nevertheless, CD36 also partially mediates UA-, but not LPS-, induced IL-6 and MIF production (Fig. 5C).

Because UA is a low-m.w. substance, it is unlikely that it is recognized by SRs, as they generally recognize anionic high-m.w. substances, as noted above. However, based on the hydrophobicity of this compound, it is reasonable to assume that some portions of UA aggregates present in culture medium are recognized by CD36. In fact, 18–33% of the triterpenoids, at a concentration of 4 µM, were revealed to be aggregated in culture medium containing 0.1% DMSO (Fig. 7), which has been widely used as a vehicle in a number of reports. Interestingly, there was a positive correlation between the aggregated UA concentration and IL-1beta production (Fig. 6). Furthermore, the ability for inducing IL-1beta was seen only with UA and not the other six triterpenoids, all of which demonstrated medium solubility similar to that of UA (Fig. 7). At present, there are no reasonable explanations for these puzzling outcomes; however, we speculate that aggregated UA, but not other triterpenoids, may have a particular structure in which its anionic moiety may be revealed for CD36 recognition. We hope to address this issue in the near future. Our results with the SPR biosensor demonstrated that UA binds to CD36 on not only pM{phi} but also RAW264.7 macrophages (Fig. 5D). Recently, we reported that UA promoted MIF release via ERK2 activation in nonstimulated RAW264.7 cells (28), whereas You et al. (27) presented similar findings and noted that UA induced iNOS and TNF-{alpha} expression via NF-{kappa}B activation in the same cell lines. Because UA binds to RAW264.7 cells, in which CD36 is expressed in a constitutive manner (data not shown), the effects of UA shown in our experiments with RAW264.7 cells may also be mediated by binding to this SR.

The predominant sources of ROS in sites of inflammation are phagocytes, including neutrophils, monocytes, and macrophages, with NOX responsible for O2– generation (47). That enzyme is dormant in resident cells but becomes activated to generate ROS upon exposure to bacteria, chemical stimuli, or calcium influx though a receptor-regulated channel (48). The present findings demonstrated that UA induced ROS generation for activating ERK1/2 and p38 MAPK and the resultant release of IL-1beta (Figs. 2 and 4). Of note, blockade of UA-induced ROS by an NOX inhibitor, NAC (antioxidant), and EDTA (calcium chelator) resulted in a decrease in ERK1/2 and p38 MAPK activities along with IL-1beta production (Fig. 4). Conversely, Schweyer et al. (49) provided experimental evidence that both MEK1/2 and ERK1/2 activation was mediated by ROS, and Fubini et al. (50) showed that silica-induced generation of ROS induced ERK1/2 activation and increased the expression of IL-1beta in cell culture models.

MAPKs control a number of cellular events, including differentiation, proliferation, and death (51). In this study, we used specific inhibitors to identify which MAPKs are involved in IL-1beta release. Our data obtained with Western blotting (Fig. 2) and pharmacological blockades (Fig. 3) strongly suggest that UA induces secretion of IL-1beta via the ERK1/2 and p38 MAPK pathways but not that of JNK1/2. In support of these findings, both the ERK1/2 and p38 MAPK pathways have been reported necessary for optimal cytokine gene expression in LPS-stimulated monocytes and macrophages (52). Similarly, Hsu et al. (53) reported that LPS-induced ROS generation activated the ERK1/2 and p38 MAPK pathways and also regulated the release of IL-1beta in mouse macrophages. The rate of inhibition of IL-1beta production by the specific inhibitors of MEK1/2 and p38 MAPK in the present study ranged from 43 to 67% (Fig. 3C), whereas the expressions of IL-1beta mRNA and protein were abolished by these inhibitors (Fig. 3A), suggesting that MAPKs do not contribute to the posttranslational mechanism. Transcriptional factors, such as NF-{kappa}B, activator protein-1, cAMP-response element-binding protein, and NF-IL6, are known to be involved in the transcriptional regulation of IL-1beta expression (54, 55, 56). Previous reports have also shown that MAPK-mediated signal pathways contribute, in part, to the transcriptional activities of those factors (57, 58, 59, 60). Thus, the above mentioned transcription factors may be crucial for UA-induced IL-1beta expression.

Some cytokines such as TNF-{alpha} and IL-6 have a secretory signal peptide, which directs these proteins into the classical endoplasmic reticulum-to-Golgi secretory pathway for rapid secretion after synthesis (8, 61, 62). In contrast, IL-1beta is a unique cytokine because it is not secreted via the classical exocytic pathway (63), and the lack of a secretory signal peptide hampers its targeting of the endoplasmic reticulum. ABC transporters are known to transport leaderless secretory protein (64). In this study, pretreatment with glibenclamide, an ABC transporter inhibitor, blocked UA-induced IL-1beta release. This result is consistent with previous reports by Zhou et al. (11) and Hamon et al. (12) who showed that the ABC transporter contributes to the secretion of IL-1beta from macrophages (11, 12).

Increasing evidence suggests that certain phytochemicals have marked anti-inflammatory and cancer chemopreventive properties (65, 66). UA is one such compound that has attracted considerable interest, based on its remarkable biological functions (17, 23, 24). For example, our group previously showed that UA has an inhibitory effect on 12-O-tetradecanoylphorbol-13-acetate-induced skin tumor promotion in mice (20). In addition, the compound attenuated LPS- or IFN-{gamma}-induced iNOS and cyclooxygenase-2 expression through NF-{kappa}B abrogation in macrophages (26). In contrast, as noted above, UA-induced MIF release via activation of ERK2 and iNOS and TNF-{alpha} expression via activation of NF-{kappa}B in resting macrophages (27, 28). More recently, we reported that topical application of UA significantly increased proinflammatory gene expression in mouse skin (67). Those findings along with the present results led us to hypothesize that the pro- and anti-inflammatory effects of UA are dependent on the biological status of cells and tissues.

In conclusion, our results showed that aggregated UA enhanced IL-1beta secretion at transcriptional, translational, and posttranslational levels via its binding with CD36 for generating ROS, thereby activating the ERK1/2 and p38 MAPK pathways, and caspase-1, and releasing IL-1beta protein via the ABC transporter in resident murine pM{phi} (Fig. 9). In addition, UA also dramatically induced IL-1beta secretion and MPO activity in our in vivo model (Fig. 8). Although UA has long been known as an effective anti-inflammatory and anticarcinogenic agent in vivo by its abilities to counteract endogenous and exogenous stimuli, further extensive evaluations regarding the effects of UA on nontreated tissues are necessary to determine the risks and benefits of this triterpenoid.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare of Japan (to A.M.). Back

2 Address correspondence and reprint requests to Dr. Hajime Ohigashi, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kitashirakawa Oiwake-tyo, Sakyo-ku, Kyoto 606-8502, Japan. E-mail address: ohigashi{at}kais.kyoto-u.ac.jp Back

3 Abbreviations used in this paper: MIF, macrophage migration inhibitory factor; ABC, ATP binding cassette transporter; DCFH-DA, 2,7'-dichlorofluorescein diacetate; DPI, diphenyleneiodonium; DSS, dextran sulfate sodium; EDTA, ethylene diamine tetraacetic acid; ICE, IL-1beta-converting enzyme; iNOS, inducible nitric oxide synthase; MEK, MAPK/ERK kinase; MKK, MAPK kinase; MPO, myeloperoxidase; NAC, N-acetyl-L-cysteine; NOX, NADPH oxidase; oxLDL, oxidized low-density lipoprotein; PKC, protein kinase C; pM{phi}, peritoneal macrophage; ROS, reactive oxygen species; SPR, surface plasmon resonance; SR, scavenger receptor; UA, ursolic acid. Back

Received for publication September 7, 2006. Accepted for publication January 30, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Takemura, R., Z. Werb. 1984. Secretory products of macrophages and their physiological functions. Am. J. Physiol. 246: (1 Pt. 1):C1-C9. [Medline]
  2. Fujiwara, N., K. Kobayashi. 2005. Macrophages in inflammation. Curr. Drug Targets Inflamm. Allergy 4: 281-286. [Medline]
  3. Nathan, C. F.. 1987. Secretory products of macrophages. J. Clin. Invest. 79: 319-326. [Medline]
  4. Sibille, Y., H. Y. Reynolds. 1990. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am. Rev. Respir. Dis. 141: 471-501. [Medline]
  5. Cominelli, F., L. Kam. 1993. Inflammatory mediators of inflammatory bowel disease. Curr. Opin. Gastroenterol. 9: 534-539.
  6. Ishiguro, Y.. 1999. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J. Gastroenterol. 34: 66-74. [Medline]
  7. Dinarello, C. A.. 1998. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16: 457-499. [Medline]
  8. Lonnemann, G., S. Endres, J. W. Van der Meer, J. G. Cannon, K. M. Koch, C. A. Dinarello. 1989. Differences in the synthesis and kinetics of release of interleukin-1{alpha}, interleukin-1beta and tumor necrosis factor from human mononuclear cells. Eur. J. Immunol. 19: 1531-1536. [Medline]
  9. Thornberry, N. A., H. G. Bull, J. R. Calaycay, K. T. Chapman, A. D. Howard, M. J. Kostura, D. K. Miller, S. M. Molineaux, J. R. Weidner, J. Aunins. 1992. A novel heterodimeric cysteine protease is required for interleukin-1beta processing in monocytes. Nature 356: 768-774. [Medline]
  10. Dinarello, C. A.. 1997. Interleukin-1. Cytokine Growth Factor Rev. 8: 253-265. [Medline]
  11. Zhou, X., T. Engel, C. Goepfert, M. Erren, G. Assmann, A. von Eckardstein. 2002. The ATP binding cassette transporter A1 contributes to the secretion of interleukin-1beta from macrophages but not from monocytes. Biochem. Biophys. Res. Commun. 291: 598-604. [Medline]
  12. Hamon, Y., M. F. Luciani, F. Becq, B. Verrier, A. Rubartelli, G. Chimini. 1997. Interleukin-1beta secretion is impaired by inhibitors of the ATP binding cassette transporter, ABC1. Blood 90: 2911-2915. [Abstract/Free Full Text]
  13. Cappello, M., S. Keshav, C. Prince, D. P. Jewell, S. Gordon. 1992. Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridization. Gut 33: 1214-1219. [Abstract/Free Full Text]
  14. Iwakura, Y.. 2005. Interleukin-1 in pathogenesis of rheumatoid arthritis. Nippon Rinsho. 63: 153-157.
  15. Savendahl, L., L. E. Underwood, K. M. Haldeman, M. H. Ulshen, P. K. Lund. 1997. Fasting prevents experimental murine colitis produced by dextran sulfate sodium and decreases interleukin-1beta and insulin-like growth factor I messenger ribonucleic acid. Endocrinology 138: 734-740. [Abstract/Free Full Text]
  16. Kwon, K. H., A. Murakami, T. Tanaka, H. Ohigashi. 2005. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of proinflammatory gene expression. Biochem. Pharmacol. 69: 395-406. [Medline]
  17. Manez, S., M. C. Recio, R. M. Giner, J. L. Rios. 1997. Effect of selected triterpenoids on chronic dermal inflammation. Eur. J. Pharmacol. 334: 103-105. [Medline]
  18. Liu, J.. 1995. Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 49: 57-68. [Medline]
  19. Mahato, S. B., S. K. Sarkar, G. Poddar. 1988. Triterpenoid saponins. Photochemistry 27: 3037-3067.
  20. Tokuda, H., H. Ohigashi, K. Koshimizu, Y. Ito. 1986. Inhibitory effects of ursolic and oleanolic acid on skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Lett. 33: 279-285. [Medline]
  21. Deepak, M., S. S. Handa. 2000. Antiinflammatory activity and chemical composition of extracts of Verbena officinalis. Phytother. Res. 14: 463-465. [Medline]
  22. Min, B. S., Y. H. Kim, S. M. Lee, H. J. Jung, J. S. Lee, M. K. Na, C. O. Lee, J. P. Lee, K. Bae. 2000. Cytotoxic triterpenes from Crataegus pinnatifida. Arch. Pharm. Res. 23: 155-158. [Medline]
  23. Ryu, S. Y., M. H. Oak, S. K. Yoon, D. I. Cho, G. S. Yoo, T. S. Kim, K. M. Kim. 2000. Anti-allergic and anti-inflammatory triterpenes from the herb of Prunella vulgaris. Planta Med. 66: 358-360. [Medline]
  24. Najid, A., A. Simon, J. Cook, H. Chable-Rabinovitch, C. Delage, A. J. Chulia, M. Rigaud. 1992. Characterization of ursolic acid as a lipoxygenase and cyclooxygenase inhibitor using macrophages, platelets and differentiated HL60 leukemic cells. FEBS Lett. 299: 213-217. [Medline]
  25. Hollosy, F., M. Idei, G. Csorba, E. Szabo, G. Bokonyi, A. Seprodi, G. Meszaros, B. Szende, G. Keri. 2001. Activation of caspase-3 protease during the process of ursolic acid and its derivative-induced apoptosis. Anticancer Res. 21: 3485-3491. [Medline]
  26. Suh, N., T. Honda, H. J. Finlay, A. Barchowsky, C. Williams, N. E. Benoit, Q. W. Xie, C. Nathan, G. W. Gribble, M. B. Sporn. 1998. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res. 58: 717-723. [Abstract/Free Full Text]
  27. You, H. J., C. Y. Choi, J. Y. Kim, S. J. Park, K. S. Hahm, H. G. Jeong. 2001. Ursolic acid enhances nitric oxide and tumor necrosis factor {alpha} production via nuclear factor-{kappa}B activation in the resting macrophages. FEBS Lett. 509: 156-160. [Medline]
  28. Ikeda, Y., A. Murakami, H. Ohigashi. 2005. Ursolic acid promotes the release of macrophage migration inhibitory factor via ERK2 activation in resting mouse macrophages. Biochem. Pharmacol. 70: 1497-1505. [Medline]
  29. Kwon, K. H., K. I. Kim, W. J. Jun, D. H. Shin, H. Y. Cho, B. S. Hong. 2002. In vitro and in vivo effects of macrophage-stimulatory polysaccharide from leaves of Perilla frutescens var. crispa. Biol. Pharm. Bull. 25: 367-371. [Medline]
  30. Perdue, M. H., J. K. Ramage, D. Burget, J. Marshall, S. Masson. 1989. Intestinal mucosa injury is associated with mast cell activation and leukotriene generation during Nippostrongylus-induced inflammation in the rat. Dig. Dis. Sci. 34: 724-731. [Medline]
  31. Bradley, P. P., D. A. Priebat, R. D. Christensen, G. Rothstein. 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Darmatol. 78: 206-209.
  32. Boullier, A., D. A. Bird, M. K. Chang, E. A. Dennis, P. Friedman, K. Gillotre-Taylor, S. Horkko, W. Palinski, O. Quehenberger, P. Shaw, et al 2001. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann. NY Acad. Sci. 947: 214-222. [Medline]
  33. van Berkel, T. J., R. Out, M. Hoekstra, J. Kuiper, E. Biessen, M. van Eck. 2005. Scavenger receptors: friend or foe in atherosclerosis?. Curr. Opin. Lipidol. 16: 525-535. [Medline]
  34. Yu, J. H., J. W. Lim, H. Kim, K. H. Kim. 2005. NADPH oxidase mediates interleukin-6 expression in cerulein-stimulated pancreatic acinar cells. Int. J. Biochem. Cell Biol. 37: 1458-1469. [Medline]
  35. Kanakaraj, P., P. H. Schafer, D. E. Cavender, Y. Wu, K. Ngo, P. F. Grealish, S. A. Wadsworth, P. A. Peterson, J. J. Siekierka, C. A. Harris, W. P. Fung-Leung. 1998. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J. Exp. Med. 187: 2073-2079. [Abstract/Free Full Text]
  36. Fukuzawa, J., J. Nishihira, N. Hasebe, T. Haneda, J. Osaki, T. Saito, T. Nomura, T. Fujino, N. Wakamiya, K. Kikuchi. 2002. Contribution of macrophage migration inhibitory factor to extracellular signal-regulated kinase activation by oxidative stress in cardiomyocytes. J. Biol. Chem. 277: 24889-24895. [Abstract/Free Full Text]
  37. Shimaoka, T., T. Nakayama, N. Kume, S. Takahashi, J. Yamaguchi, M. Minami, K. Hayashida, T. Kita, J. Ohsumi, O. Yoshie, S. Yonehara. 2003. Cutting edge: SR-PSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain. J. Immunol. 171: 1647-4651. [Abstract/Free Full Text]
  38. Moore, K. J., J. El-Khoury, L. A. Medeirou, K. Terada, C. Geula, A. D. Luster, M. W. Freeman. 2002. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J. Biol. Chem. 277: 47373-47379. [Abstract/Free Full Text]
  39. Nishimura, S., M. Akagi, K. Yoshida, S. Hayakawa, T. Sawamura, H. Munakata, C. Hamanishi. 2004. Oxidized low-density lipoprotein (ox-LDL) binding to lectin-like ox-LDL receptor-1 (LOX-1) in cultured bovine articular chondrocytes increases production of intracellular reactive oxygen species (ROS) resulting in the activation of NF-{kappa}B. Osteoarthritis Cartilage 12: 568-576. [Medline]
  40. Febbraio, M., D. P. Hajjar, R. L. Silverstein. 2001. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108: 785-791. [Medline]
  41. Talle, M. A., P. E. Rao, E. Westberg, N. Allegar, M. Makowski, R. S. Mittler, G. Goldstein. 1983. Patterns of antigenic expression on human monocytes as defined by monoclonal antibodies. Cell. Immunol. 78: 83-99. [Medline]
  42. Li, Y. S., Y. J. Shyy, J. G. Wright, A. J. Valente, J. F. Cornhill, P. E. Kolattukudy. 1993. The expression of monocyte chemotactic protein (MCP-1) in human vascular endothelium in vitro and in vivo. Mol. Cell. Biochem. 126: 61-68. [Medline]
  43. Knowles, D. M., II, B. Tolidjian, C. Marboe, V. D’Agati, M. Grimes, L. Chess. 1984. Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium. J. Immunol. 132: 2170-2173. [Medline]
  44. Mietus-Snyder, M., M. S. Gowri, R. E. Pitas. 2000. Class A scavenger receptor up-regulation in smooth muscle cells by oxidized low density lipoprotein: enhancement by calcium flux and concurrent cyclooxygenase-2 up-regulation. J. Biol. Chem. 275: 17661-17670. [Abstract/Free Full Text]
  45. Leng, L., C. N. Metz, Y. Fang, J. Xu, S. Donnelly, J. Baugh, T. Delohery, Y. Chen, R. A. Mitchell, R. Bucala. 2003. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197: 1467-1476. [Abstract/Free Full Text]
  46. Murakami, S., H. Takashima, M. Sato-Watanabe, S. Chonan, K. Yamamoto, M. Saitoh, S. Saito, H. Yoshimura, K. Sugawara, J. Yang, et al 2004. Ursolic acid, an antagonist for transforming growth factor (TGF)-beta1. FEBS Lett. 566: 55-59. [Medline]
  47. Bokoch, G. M.. 1995. Regulation of the phagocyte respiratory burst by small GTP-binding proteins. Trends Cell Biol. 5: 109-113. [Medline]
  48. Cathcart, M. K.. 2004. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24: 23-28. [Abstract/Free Full Text]
  49. Schweyer, S., A. Soruri, A. Heintze, H. J. Radzun, A. Fayyazi. 2004. The role of reactive oxygen species in cisplatin-induced apoptosis in human malignant testicular germ cell lines. Int. J. Oncol. 25: 1671-1676. [Medline]
  50. Fubini, B., A. Hubbard. 2003. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic. Biol. Med. 34: 1507-1516. [Medline]
  51. Lewis, T. S., P. S. Shapiro, N. G. Ahn. 1998. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74: 49-139. [Medline]
  52. Carter, A. B., M. M. Monick, G. W. Hunninghake. 1999. Both Erk and p38 kinases are necessary for cytokine gene transcription. Am. J. Respir. Cell Mol. Biol. 20: 751-758. [Abstract/Free Full Text]
  53. Hsu, H. Y., M. H. Wen. 2002. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J. Biol. Chem. 277: 22131-22139. [Abstract/Free Full Text]
  54. Serkkola, E., M. Hurme. 1993. Synergism between protein-kinase C and cAMP-dependent pathways in the expression of the interleukin-1beta gene is mediated via the activator-protein-1 (AP-1) enhancer activity. Eur. J. Biochem. 213: 243-249. [Medline]
  55. Hiscott, J., J. Marois, J. Garoufalis, M. D’Addario, A. Roulston, I. Kwanm, N. Pepin, J. Lacoste, H. Nguyen, G. Bensi, et al 1993. Characterization of a functional NF-{kappa}B site in the human interleukin-1beta promoter: evidence for a positive autoregulatory loop. Mol. Cell. Biol. 13: 6231-6240. [Abstract/Free Full Text]
  56. Shirakawa, F., K. Saito, C. A. Bonagura, D. L. Galson, M. J. Fenton, A. C. Webb, P. E. Auron. 1993. The human prointerleukin-1beta gene requires DNA sequences both proximal and distal to the transcription start site for tissue-specific induction. Mol. Cell. Biol. 13: 1332-1344. [Abstract/Free Full Text]
  57. Wang, D., A. Richmond. 2001. Nuclear factor-{kappa}B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 276: 3650-3659. [Abstract/Free Full Text]
  58. Karin, M.. 1995. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270: 16483-16486. [Free Full Text]
  59. Chang, F., L. S. Steelman, J. T. Lee, J. G. Shelton, P. M. Navolanic, W. L. Blalock, R. A. Franklin, J. A. McCubrey. 2003. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17: 1263-1293. [Medline]
  60. Eliopoulos, A. G., C. D. Dumitru, C. C. Wang, J. Cho, P. N. Tsichlis. 2002. Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J. 21: 4831-4840. [Medline]
  61. Kriegler, M., C. Perez, K. DeFay, I. Albert, S. D. Lu. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53: 45-53. [Medline]
  62. Santhanam, U., J. Ghrayeb, P. B. Sehgal, L. T. May. 1989. Post-translational modifications of human interleukin-6. Arch. Biochem. Biophys. 274: 161-170. [Medline]
  63. Singer, I. I., S. Scott, G. L. Hall, G. Limjuco, J. Chin, J. A. Schmidt. 1988. Interleukin-1beta is localized in the cytoplasmic ground substance but is largely absent from the Golgi apparatus and plasma membranes of stimulated human monocytes. J. Exp. Med. 167: 389-407. [Abstract/Free Full Text]
  64. K. Kuchler, II, and A. Rubartelli, II, and B. Holland, II, eds. Unusual Secretory Pathways: From Bacteria to Man 1997 Landes Bioscience, Austin.
  65. Waladkhani, A. R., M. R. Clemens. 1998. Effect of dietary phytochemicals on cancer development (review). Int. J. Mol. Med. 1: 747-753. [Medline]
  66. Kelloff, G. J.. 2000. Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res. 78: 199-334. [Medline]
  67. Ikeda, Y., A. Murakami, T. Nishizawa, H. Ohigashi. 2006. Ursolic acid enhances cyclooxygenases and tumor necrosis factor {alpha} expression in mouse skin. Biosci. Biotechnol. Biochem. 70: 1033-1037. [Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikeda, Y.
Right arrow Articles by Ohigashi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikeda, Y.
Right arrow Articles by Ohigashi, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS